U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 56

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letter dated November 14, 2008,
1. The William W. Backus Hospital	3. License number 06-11734-02 is amended in its entirety to read as follows:
2. 326 Washington Street Norwich, Connecticut 06360	4. Expiration date September 30, 2013
	5. Docket No. 030-01287 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 400 millicuries
D. Iodine-125 permitted by 10 CFR 35.400	D. Sealed sources (Amersham Model 6711)	D. 500 millicuries
E. Gadolinium-153 permitted by 10 CFR 35.500	E. Sealed sources (IPL Model 3409)	E. 90 millicuries per source and 176 millicuries total

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
B. Any imaging and localization study permitted by 10 CFR 35.200.
C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300, for which the patient can be released under the provisions of 10 CFR 35.75.
D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
E. Diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
06-11734-02

Docket or Reference Number
030-01287

Amendment No. 56

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 326 Washington Street, Norwich, Connecticut.

11. The Radiation Safety Officer for this license is Jeffrey C. Rudikoff, M.D.

12. Licensed material is only authorized for use by, or under the supervision of:

    A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

    B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
William Daniel Donovan, M.D.	35.100; 35.200; 35.500
Phillip Kohanski, M.D.	35.100; 35.200; Oral administration of sodium iodide Iodine-131; Parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV; 35.500
Meena Savur Moran, M.D.	Iodine-125 for manual brachytherapy procedures
Sa-id Esfahanian, M.D.	35.100; 35.200
Jeffrey C. Rudikoff, M.D.	35.100; 35.200; 35.300 35.500
Kenneth B. Roberts, M.D.	Iodine-125 for manual brachytherapy procedures
Gail B. Weingast, M.D.	35.100; 35.200; Oral administration of sodium iodide Iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction
Jennifer R.Q. Willmann-Siegelman, M.D.	35.100; 35.200
James Thomas, M.D.	35.100; 35.200
Ajay I. Dalal, M.D.	35.100; 35.200
Felicia Cuomo, M.D.	35.100; 35.200

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
06-11734-02

Docket or Reference Number
030-01287

Amendment No. 56

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

    A. Letter dated August 6, 2003 (ML032320427)
    B. Letter dated September 12, 2003 (ML032650637)
    C. Letter dated April 27, 2004 (ML041550791)
    D. Letter dated August 10, 2004 (ML042390437)
    E. Letter dated September 30, 2004 (ML042920397)

For the U.S. Nuclear Regulatory Commission

Date January 13, 2009

By ***Original signed by Penny Lanzisera***

Penny Lanzisera
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406